Contineum Therapeutics, Inc. Class A Common Stock (CTNM) support and resistance · $429.6M cap
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
This page maps Contineum Therapeutics, Inc. Class A Common Stock (CTNM) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported CTNM revenue for 2024-09-30 was $0. Net income was -$27.7M. CTNM currently screens at market cap $429.6M.
CTNM currently screens at market cap $429.6M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new CTNM 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the CTNM quote page for the session range and the stock page for the full model.
Not investment advice.